Further details re equity instruments to be issued to CEO
Released
Released
Announcement PDF
ASX Announcement
FURTHER DETAILS REGARDING EQUITY INSTRUMENTS TO
BE ISSUED TO THE CEO
30 April 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company)
(ASX: MYX) refers to its announcement on 23 February 2026 which included a summary of the key
terms of Mr Aaron Gray’s employment agreement.
Set out in the attachment to this announcement are further details relating to the equity
instruments to be issued to Mr Gray.
Mayne Pharma confirms that Mr Gray is not involved in any remuneration decisions regarding the
issue of incentives to him.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Board Chair.
Email Alerts
To register for an email alert service to receive Mayne Pharma announcements released to the
Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investor-
relations/email-alerts/
Follow us on LinkedIn
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
ASX Announcement
Page 2
Summary of key terms of equity instruments to be issued to Mr Gray
Sign-on bonus Long Term Incentive (LTI) award
Grant value US$300,000 The grant value, or target opportunity, of Mr Gray’s
LTI is equivalent to 150% of Mr Gray’s base salary
of US$600,000, being US$900,000.
For FY26, Mr Gray’s participation is pro-rated
between Mr Gray’s time as CFO and CEO. This
means that for FY26, the grant value is
US$654,781.
Number and
price of
Performance
Rights
Mr Gray will be issued with Restricted
Stock Unit Performance Rights (RSUs)
under the Company's new Omnibus
Equity Incentive Plan Rules (OEIP).
The number of RSUs to be granted to Mr
Gray will be calculated by dividing the
grant value (converted to Australian
Dollars) by the Market Price.
The Market Price is the five-day volume
weighted average price at which Mayne
Pharma Shares were traded on the ASX
up to the grant date.
Mr Gray will be issued with a combination of RSUs
and Performance Rights under the OEIP.
The total number of equity instruments to be
granted to Mr Gray will be calculated by dividing
the grant value (converted to Australian Dollars)
by the Market Price.
The Market Price is the five-day volume weighted
average price at which Mayne Pharma Shares
were traded on the ASX up to the grant date.
One-third of the equity instruments will be
granted in the form of RSUs and two-thirds of the
equity instruments will be granted in the form of
Performance Rights.
Other key
terms of OEIP
If the vesting criteria (as set out below) are met:
1. the RSUs and Performance Rights will be automatically exercised at the date they vest;
and
2. the Company’s intention is to settle the RSUs and Performance Rights by providing Mr
Gray with one fully paid ordinary share for each vested RSUs or Performance Right (as
applicable), with Mr Gray expected to sell a portion of these Shares to meet withholding
tax obligations. Alternatively, the Company may “net settle” with Mr Gray, so that the
Company pays the relevant tax directly to the tax authorities and provides Mr Gray with
the after-tax number of Shares.
The Board may elect to settle any RSUs and Performance Rights vesting by way of a cash
payment (rather than Shares).
Mr Gray will not have any rights to dividends, rights to vote or rights to the capital of the
Company from a RSU or Performance Right, unless and until they are exercised and satisfied
by the provision of Shares.
However, the OEIP allows the Board to determine at its absolute discretion that a participant
is entitled to receive a 'Dividend Equivalent Payment' in respect of some or all of the Rights
they hold. For example, the Board may make such a determination where a significant
business asset is disposed of, and existing shareholders are paid a dividend sourced from that
disposal.
In exercising this power underthe OEIP,theBoard will consider whetherit is fair and equitable
to all shareholders, option and rights holders, having regard to any transactions or significant
events that have occurred.
ASX Announcement
Page 3
Sign-on bonus Long Term Incentive (LTI) award
Vesting
criteria
The RSUs will vest immediately at the
time of issue.
RSUs issued to Mr Gray will vest provided that Mr
Gray is employed by the Company on the date
which is three years after they are issued.
Performance Rights issued to Mr Gray will vest
where an absolute total shareholder return (TSR)
growth condition is met over the three years.
20% of the Performance Rights will vest for
compound annual absolute TSR growth of 8%. All
of the Performance Rights will vest for compound
annual absolute TSR growth of 15%. Vesting will
occur on a straight-line basis for performance
between these two points.
The TSR growth may be adjusted in the event of
certain corporate actions (in a manner to be
determined by the Board). Such corporate
actions include a share dividend, share
consolidation or share split, spin-off/demerger,
rights issue and a convertible note conversion.
Performance
period
The RSUs will vest immediately at the
time of issue.
If the vesting criteria are met, the RSUs and
Performance Rights will vest at the end of 3 years.
The test date for the RSUs and Performance
Rights has been set at 3 years following the date
of issue.
Trading
restrictions
The RSUs and Performance Rights are not able to be sold or transferred by Mr Gray until they
vest, all vesting conditions and exercise conditions have been met and they are not subject
to dealing restrictions.
The RSUs and Performance Rights do not give Mr Gray any rights to a Share unless and until
the vesting conditions for the RSUs and Performance Rights are met and Shares are allocated
on exercise.
Disposal of Shares allocated on exercise of RSUs and Performance Rights are subject to the
Company’s Security Trading Policy while Mr Gray is an employee.
Cessation of
employment
If Mr Gray ceases employment:
• he will retain all vested RSUs and Performance Rights; and
• treatment of unvested RSUs and Performance Rights depends on a range of factors,
such as the reason for Mr Gray’s departure and his tenure. If he ceases employment by
reason of retirement, redundancy or another ‘Good Leaver’ category determined by the
Board, Mr Gray will retain a pro-rated portion of unvested instruments based on time
served against the performance period. Remaining unvested awards will lapse and be
forfeited unless the Board determines that he is able to retain a higher proportion. If Mr
Gray is an 'Ineligible Leaver" all unvested RSUs and Performance Rights will lapse and
he will have 6 months to exercise any vested RSUs and Performance Rights.
Change of
control
Unless otherwise specified in the invitation letter, all RSUs and Performance Rights will vest if
a change of control event occurs, unless the Board determines otherwise. The Board may
determine prior to the change of control event that unvested RSUs and Performance Rights
should remain unvested and lapse, waive vesting or exercise conditions, buy-back or cash
settle RSUs and Performance Rights or specify some other treatment.
Clawback The Board may claw back some or all of the value of any equity awards in certain
circumstances, such as fraud, misconduct, negligence, a material misstatement in the
Company's financial reporting or material financial or reputational damage to the Company.
Share your feedback
Discover